Cargando…

Decisions in health technology assessment: should we speak with one voice?

Decisions regarding the regulation of individual medicines differ from country to country. In the case of Relenza, Mulinari and Davis (Health Res Policy Syst 15:93, 2017) have suggested that these inconsistencies are primarily due to processes, statistical methodologies and technical capacity varyin...

Descripción completa

Detalles Bibliográficos
Autor principal: Merlin, Tracy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237006/
https://www.ncbi.nlm.nih.gov/pubmed/30442146
http://dx.doi.org/10.1186/s12961-018-0385-y
_version_ 1783371131281997824
author Merlin, Tracy
author_facet Merlin, Tracy
author_sort Merlin, Tracy
collection PubMed
description Decisions regarding the regulation of individual medicines differ from country to country. In the case of Relenza, Mulinari and Davis (Health Res Policy Syst 15:93, 2017) have suggested that these inconsistencies are primarily due to processes, statistical methodologies and technical capacity varying between regulatory agencies. They go on to name specific individuals involved in the evaluation of this anti-influenza medicine and imply that differences in the judgements of these individuals has affected public policy concerning the market access of this medicine. This Commentary argues that what may appear as inconsistent decision-making may in fact be due to differences in the applicability of the evidence base to the local population and health system for which each regulator has responsibility. If health technology assessors are providing nuanced judgements on the effectiveness of a medicine for the local population, differences in regulation and reimbursement decisions are to be expected.
format Online
Article
Text
id pubmed-6237006
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62370062018-11-23 Decisions in health technology assessment: should we speak with one voice? Merlin, Tracy Health Res Policy Syst Commentary Decisions regarding the regulation of individual medicines differ from country to country. In the case of Relenza, Mulinari and Davis (Health Res Policy Syst 15:93, 2017) have suggested that these inconsistencies are primarily due to processes, statistical methodologies and technical capacity varying between regulatory agencies. They go on to name specific individuals involved in the evaluation of this anti-influenza medicine and imply that differences in the judgements of these individuals has affected public policy concerning the market access of this medicine. This Commentary argues that what may appear as inconsistent decision-making may in fact be due to differences in the applicability of the evidence base to the local population and health system for which each regulator has responsibility. If health technology assessors are providing nuanced judgements on the effectiveness of a medicine for the local population, differences in regulation and reimbursement decisions are to be expected. BioMed Central 2018-11-15 /pmc/articles/PMC6237006/ /pubmed/30442146 http://dx.doi.org/10.1186/s12961-018-0385-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Merlin, Tracy
Decisions in health technology assessment: should we speak with one voice?
title Decisions in health technology assessment: should we speak with one voice?
title_full Decisions in health technology assessment: should we speak with one voice?
title_fullStr Decisions in health technology assessment: should we speak with one voice?
title_full_unstemmed Decisions in health technology assessment: should we speak with one voice?
title_short Decisions in health technology assessment: should we speak with one voice?
title_sort decisions in health technology assessment: should we speak with one voice?
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237006/
https://www.ncbi.nlm.nih.gov/pubmed/30442146
http://dx.doi.org/10.1186/s12961-018-0385-y
work_keys_str_mv AT merlintracy decisionsinhealthtechnologyassessmentshouldwespeakwithonevoice